TH4280C3 - Pharmaceutical mixtures for the treatment of viral infections - Google Patents
Pharmaceutical mixtures for the treatment of viral infectionsInfo
- Publication number
- TH4280C3 TH4280C3 TH703000557U TH0703000557U TH4280C3 TH 4280 C3 TH4280 C3 TH 4280C3 TH 703000557 U TH703000557 U TH 703000557U TH 0703000557 U TH0703000557 U TH 0703000557U TH 4280 C3 TH4280 C3 TH 4280C3
- Authority
- TH
- Thailand
- Prior art keywords
- pharmaceutical
- derivatives
- sodium
- ritonavir
- mixtures according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 15
- 206010047461 Viral infection Diseases 0.000 title claims abstract 4
- 208000001756 Virus Disease Diseases 0.000 title claims abstract 4
- 230000017613 viral reproduction Effects 0.000 title claims abstract 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims abstract 11
- 229960000311 ritonavir Drugs 0.000 claims abstract 11
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims abstract 7
- 229960003277 atazanavir Drugs 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 7
- 229940079593 drugs Drugs 0.000 claims abstract 4
- -1 viscosity Substances 0.000 claims 6
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229960005070 ascorbic acid Drugs 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 2
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 2
- 229940068968 Polysorbate 80 Drugs 0.000 claims 2
- 229960005055 SODIUM ASCORBATE Drugs 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 230000002335 preservative Effects 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 claims 2
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- 229940072107 Ascorbate Drugs 0.000 claims 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920001451 Polypropylene glycol Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229940032147 Starch Drugs 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 150000002597 lactoses Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 229920002866 paraformaldehyde Polymers 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 229940001482 sodium sulfite Drugs 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- 241000083700 Ambystoma tigrinum virus Species 0.000 abstract 2
- 210000004369 Blood Anatomy 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000001177 retroviral Effects 0.000 abstract 2
- 230000001225 therapeutic Effects 0.000 abstract 2
Abstract
DC60 สารผสมทางเภสัชกรรมชนิดใหม่ ที่รวมสารอทาซานาเวียร์ ( Atazanavir, ATV) และริโทนา เวียร์ (Ritonavir, RTV) เข้าไว้ในรูปขนาดการให้ยาที่เป็นรูปแบบเดี่ยว เพื่อเพิ่มความสะดวกในการ รับประทานยาของผู้ป่วย ลดปัญหาการดื้อยาของเชื้อไวรัสเอชไอวี และเพื่อให้ผลเพิ่มระดับยาใน เลือดและประสิทธิภาพในการรักษาของอทาซานาเวียร์ เมื่อใช้ร่วมกับ ริโทนาเวียร์ ซึ่งเป็นประโยชน์ ในการบำบัดโรคต่างๆ ในสัตว์เลี้ยงลูกด้วยนมซึ่งรวมถึงมนุษย์ การประดิษฐ์นี้จะเป็นประโยชน์ใน การบำบัดการติดเชื้อไวรัสโดยเฉพาะอย่างยิ่งการติดเชื้อรีโทรไวรัส (retroviral inflection) ซึ่งรวมถึง ไวรัสที่ทำให้ภูมิคุ้มกันบกพร่อง (HIV) สารผสมทางเภสัชกรรมชนิดใหม่ ที่รวมสารอทาซานาเวียร์ ( Atazanavir, ATV) และริโทนา เวียร์ (Ritonavir, RTV) เข้าไว้ในรูปขนาดการให้ยาที่เป็นรูปแบบเดี่ยว เพื่อเพิ่มความสะดวกในการ รับประทานยาของผู้ป่วย ลดปัญหาการดื้อยาของเชื้อไวรัสเอชไอวี และเพื่อให้ผลเพิ่มระดับยาใน เลือดและประสิทธิภาพในการรักษาของอทาซานาเวียร์ เมื่อใช้ร่วมกับ ริโทนาเวียร์ ซึ่งเป็นประโยชน์ ในการบำบัดโรคต่างๆ ในสัตว์เลี้ยงลูกด้วยนมซึ่งรวมถึงมนุษย์ การประดิษฐ์นี้จะเป็นประโยชน์ใน การบำบัดการติดเชื้อไวรัสโดยเฉพาะอย่างยิ่งการติดเชื้อรีโทรไวรัส (retroviral inflection) ซึ่งรวมถึง ไวรัสที่ทำให้ภูมิคุ้มกันบกพร่อง (HIV) สิทธิบัตรยา DC60 New Pharmaceutical Mixture That combines atazanavir (Atazanavir, ATV) and ritonavir (Ritonavir, RTV) into a single dosing form. To increase the convenience of Taking the medicine of the patient Reduce the problem of drug resistance of the HIV virus. And to increase the drug level in Atasanavir's blood and therapeutic efficacy In combination with ritonavir, which is useful In the treatment of various diseases In mammals, including humans This invention is useful in Treatment of viral infections, in particular retroviral inflection, including immunodeficiency virus (HIV), new pharmaceutical mixtures. That combines atazanavir (Atazanavir, ATV) and ritonavir (Ritonavir, RTV) into a single dosing form. To increase the convenience of Taking the medicine of the patient Reduce the problem of drug resistance of the HIV virus. And to increase the drug level in Atasanavir's blood and therapeutic efficacy In combination with ritonavir, which is useful In the treatment of various diseases In mammals, including humans This invention is useful in Treatment of viral infections, especially retroviral inflection, including immunodeficiency virus (HIV), drug patents.
Claims (9)
Publications (2)
Publication Number | Publication Date |
---|---|
TH4280C3 true TH4280C3 (en) | 2008-06-13 |
TH4280A3 TH4280A3 (en) | 2008-06-13 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240165102A1 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
JP2005515996A5 (en) | ||
US20070225262A2 (en) | Method for the treatment of acne | |
JP2019517542A5 (en) | ||
NO20080244L (en) | Dosage control for prasugrel | |
CA2612179A1 (en) | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion | |
TWI630911B (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
CA2893836C (en) | A combination medicament comprising phenylephrine and paracetamol | |
WO2005048978A3 (en) | A controlled release pharmaceutical composition and a process for preparing the same | |
TH4280A3 (en) | Pharmaceutical mixtures for the treatment of viral infections | |
TH4280C3 (en) | Pharmaceutical mixtures for the treatment of viral infections | |
JPWO2021202419A5 (en) | ||
JP2006508134A (en) | Pharmaceutical composition | |
US20190216725A1 (en) | Drug delivery system for the delivery of integrase inhibitors | |
JP2019533672A5 (en) | ||
AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
TH3651C3 (en) | Pharmaceutical mixtures for the treatment of viral infections | |
TH3651A3 (en) | Pharmaceutical mixtures for the treatment of viral infections | |
KR101362679B1 (en) | Retard formulation for pralnacasan | |
AU2013211546B1 (en) | A Medicament | |
Kobayashi et al. | A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV | |
US11833189B1 (en) | Sublingual Semaglutide-BPC 157 combination for weight loss | |
WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
TH11837A3 (en) | Pharmaceutical mixtures for the treatment of viral infections and their production processes | |
TH11837C3 (en) | Pharmaceutical mixtures for the treatment of viral infections and their production processes |